Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Galectin Therapeutics Inc. (NASDAQ: GALT) shares soared 21.72 percent to close at $6.78 a share Monday. The stock traded between $6.01 and $7.95 on volume of 1.36 million shares traded. The company announced that GR-MD-O2 has received Fast Track designation from the FDA for the treatment of fatty liver disease with advanced fibrosis. Shares of Galectin Therapeutics have gained approximately 230.0 percent year-to-date.
Get more information on Galectin Therapeutics and free access to the in-depth equity report at:
MannKind Corporation (NASDAQ: MNKD) shares declined 4.95 percent to close at $7.10 a share Monday. The stock traded between $7.00 and $7.58 on volume of 15.43 million shares traded. The company reported a net loss of $46.1 million for the second quarter of 2013, compared to a net loss of $36.6 million in the year ago quarter. Shares of MannKind have gained over 200.0 percent year-to-date.
Get more information on MannKind and free access to the in-depth equity report at:
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares declined 8.95 percent to close at $4.68 a share Monday. The stock traded between $4.56 and $5.06 on volume of 506,255 shares traded. The company reported net loss for the second quarter grew to $12.3 million for the second quarter of 2013, from a net loss of $10.7 million a year ago. Shares of Progenics Pharmaceuticals have gained approximately 57.0 percent year-to-date.
Get more information on Progenics Pharmaceuticals and free access to the in-depth equity report at:
Vical Incorporated (NASDAQ: VICL) shares plunged 57.26 percent to close at $1.53 a share Monday. The stock traded between $1.37 and $1.61 on volume of 30.90 million shares traded. The company announced that its melanoma drug, Allovectin, failed to show “statistically significant improvement” in a recent study.
Get more information on Vical and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...